BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34962924)

  • 1. Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021.
    Ayodele O; Ren K; Zhao J; Signorovitch J; Jonsson Funk M; Zhu J; Bao Y; Gondek K; Keenan H;
    PLoS One; 2021; 16(12):e0261707. PubMed ID: 34962924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
    Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
    PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
    Mehta HB; An H; Andersen KM; Mansour O; Madhira V; Rashidi ES; Bates B; Setoguchi S; Joseph C; Kocis PT; Moffitt R; Bennett TD; Chute CG; Garibaldi BT; Alexander GC;
    Ann Intern Med; 2021 Oct; 174(10):1395-1403. PubMed ID: 34399060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement.
    Best JH; Kong AM; Kaplan-Lewis E; Brawley OW; Baden R; Zazzali JL; Miller KS; Loveless J; Jariwala-Parikh K; Mohan SV
    J Med Virol; 2021 Sep; 93(9):5367-5375. PubMed ID: 33913536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
    Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
    JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life use of remdesivir in hospitalized patients with COVID-19.
    Garcia-Vidal C; Meira F; Cózar-Llistó A; Dueñas G; Puerta-Alcalde P; Garcia-Pouton N; Chumbita M; Cardozo C; Hernandez-Meneses M; Alonso-Navarro R; Rico V; Agüero D; Bodro M; Morata L; Jordan C; Lopera C; Ambrosioni J; Segui F; Grafia N; Castro P; García F; Mensa J; Martínez JA; Sanjuan G; Soriano A;
    Rev Esp Quimioter; 2021 Apr; 34(2):136-140. PubMed ID: 33675220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
    Cantini F; Goletti D; Petrone L; Najafi Fard S; Niccoli L; Foti R
    Drugs; 2020 Dec; 80(18):1929-1946. PubMed ID: 33068263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
    Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
    JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis.
    Veronese N; Di Gennaro F; Frallonardo L; Ciriminna S; Papagni R; Carruba L; Agnello D; De Iaco G; De Gennaro N; Di Franco G; Naro L; Brindicci G; Rizzo A; Bavaro DF; Garlisi MC; Santoro CR; Signorile F; Balena F; Mansueto P; Milano E; Giannitrapani L; Fiordelisi D; Mariani MF; Procopio A; Lattanzio R; Licata A; Vernuccio L; Amodeo S; Guido G; Segala FV; Barbagallo M; Saracino A
    Sci Rep; 2024 Apr; 14(1):9303. PubMed ID: 38654033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system.
    Coppock D; Baram M; Chang AM; Henwood P; Kubey A; Summer R; Zurlo J; Li M; Hess B
    PLoS One; 2021; 16(6):e0252591. PubMed ID: 34115801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Remdesivir in Myasthenia gravis and COVID-19.
    Peters BJ; Rabinstein AA; DuBrock HM
    Pharmacotherapy; 2021 Jun; 41(6):546-550. PubMed ID: 33835512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
    Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
    Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.
    Congly SE; Varughese RA; Brown CE; Clement FM; Saxinger L
    Sci Rep; 2021 Sep; 11(1):17787. PubMed ID: 34493774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone.
    Bhagavan SM; Ramaswamy SB; Govindarajan R
    Medicine (Baltimore); 2021 May; 100(18):e25701. PubMed ID: 33950951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
    JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication Use Patterns in Hospitalized Patients With COVID-19 in California During the Pandemic.
    Watanabe JH; Kwon J; Nan B; Abeles SR; Jia S; Mehta SR
    JAMA Netw Open; 2021 May; 4(5):e2110775. PubMed ID: 34019090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy-A Prospective Longitudinal Study.
    Copaescu A; James F; Mouhtouris E; Vogrin S; Smibert OC; Gordon CL; Drewett G; Holmes NE; Trubiano JA
    Front Immunol; 2021; 12():646095. PubMed ID: 33815405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inpatient COVID-19 mortality has reduced over time: Results from an observational cohort.
    Bechman K; Yates M; Mann K; Nagra D; Smith LJ; Rutherford AI; Patel A; Periselneris J; Walder D; Dobson RJB; Kraljevic Z; Teo JHT; Bernal W; Barker R; Galloway JB; Norton S
    PLoS One; 2022; 17(1):e0261142. PubMed ID: 35025917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital.
    Hidalgo-Tenorio C; García-Vallecillos C; Sequera-Arquelladas S;
    Medicine (Baltimore); 2021 Sep; 100(37):e27228. PubMed ID: 34664862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.